4D Molecular legal chief sells 584 shares post-exercise

FDMT’s Chief Legal Officer exercised and sold 584 shares under a pre-arranged Rule 10b5-1 trading plan, leaving 2,959 option shares from the award outstanding.

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. (FDMT) reported that its Chief Legal Officer, Scott Bizily, exercised options for 584 shares of common stock on September 1, 2026 at an exercise price of $6.49 per share and sold the same 584 shares at $14.00 per share. The option exercise and related sale were made under a Rule 10b5-1 trading plan adopted on January 13, 2026. Following the exercise, 2,959 option shares remain outstanding from this award, which vests in equal monthly installments over four years starting June 16, 2022.

Insider Trade Summary 10b5-1

Exercise and Sale: 584 shares ($4K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Bizily Scott

Role Chief Legal Officer

Sold 584 shs ($8K)

Approx. gross sale proceeds $8K

Approx. exercise cost $4K

Approx. pre-tax spread $4K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F2	584	$0.00	$0.00
Exercise	Common Stock F1	584	$6.49	$4K
Sale	Common Stock F1	584	$14.00	$8K

Holdings After Transaction: Stock Option (Right to Buy) — 2,959 contracts (Direct); Common Stock — 8,617 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
2. F2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Key Figures

Shares exercised: 584 shares Exercise price: $6.49 per share Shares sold: 584 shares +4 more

7 metrics

Shares exercised 584 shares Options exercised on September 1, 2026 by the Chief Legal Officer

Exercise price $6.49 per share Exercise price for 584 option shares converted into common stock

Shares sold 584 shares Common shares sold on September 1, 2026 following option exercise

Sale price $14.00 per share Per-share price for the 584 common shares sold

Remaining option shares 2,959 shares Option shares reported as held after the exercise

Vesting schedule 1/48th monthly over 4 years Option vests each month from June 16, 2022 until the fourth anniversary

Rule 10b5-1 plan adoption date January 13, 2026 Date the pre-arranged trading plan governing these trades was adopted

Key Terms

Rule 10b5-1 trading plan, Vesting Commencement Date, service provider

3 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Vesting Commencement Date financial

"on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

service provider financial

"fully vested and exercisable on the fourth anniversary ... while the grantee remains a service provider"

FAQ

What insider transactions did FDMT’s Chief Legal Officer report on September 1, 2026?

FDMT’s Chief Legal Officer reported exercising options for 584 shares of common stock at $6.49 per share and selling 584 shares at $14.00 per share on September 1, 2026.

Was the FDMT insider sale on September 1, 2026 made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2026.

What is the option position remaining for the FDMT Chief Legal Officer after these transactions?

After exercising 584 shares, the reporting person holds 2,959 option shares from this award, according to the reported post-transaction option balance.

What is the vesting schedule of the FDMT stock option involved in this Form 4?

The footnote explains the option vests as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022, becoming fully vested on the fourth anniversary while the holder remains a service provider.

What prices were involved in the FDMT option exercise and share sale?

The option was exercised at an exercise price of $6.49 per share for 584 shares, and those 584 shares of common stock were sold at $14.00 per share on the same date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:56 PM Accepted by SEC EDGAR 09/03/2026 - 06:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bizily Scott

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		M(1)		584	A	$6.49	9,201	D
Common Stock	09/01/2026		S(1)		584	D	$14	8,617	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.49	09/01/2026		M(1)			584	(2)	06/17/2032	Common Stock	584	$0	2,959	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.

2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

	/s/ Scott Bizily	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)